To develop a new mucoadhesiveˆlm containing an analgesic combining clinical e‹cacy and patient comfort, we prepared and evaluated a two-layeredˆlm consisting of an adhesive layer containing indomethacin (IM) as the active ingredient and carboxyvinyl polymer (CP) as a bonding agent and a nonadhesive layer containing polyethylene glycol (PEG) to improveˆlm texture. In in vitro and in vivo adhesive tests, the optimal concentration of CP that could be applied to the mucous membrane was 0.2％ or 0.3％. Stability testing determined that the optimal storage conditions and expiration period were 4°C without shade and 4 weeks, respectively. Theˆlm was clinically evaluated in patients with oral pain. IM at concentrations of 0.5％ and 1％ provided optimum analgesic eŠects, and the eŠects were the greatest in the 1％ IM group. The addition of PEG to the nonadhesive layer reduced the number of patients experiencing discomfort at the site where theˆlm was applied. Therefore thisˆlm formulation may be useful for local analgesic application due to its low dose requirement, moderate adhesion, and comfortable texture.
INTRODUCTION
Oral mucosal pain can aŠect the activities of daily living, such as eating and sleeping, and result in disorders that may considerably reduce patient quality of life (QOL). 1) Oral adhesiveˆlms containing local anesthetics 2) or steroids 3) have been developed to improve QOL in patients with oral pain, although thesê lms have several drawbacks including discomfort due to numbness or hypoesthesia resulting from local anesthetic action,ˆlm exfoliation from the aŠected part, andˆlm hardness. In addition, the current method used forˆlm preparation requires repeated expansion and drying of the base, making it di‹cult to prepare aˆlm of uniform thickness. We investigated a simple method for preparing aˆlm of uniform thickness and developed aˆlm with moderate adhesion and good texture.
MATERIALS AND METHODS

Film Preparation
Hydroxypropyl cellulose (HPC) 150 400 cP, indomethacin (IM), and polyethylene glycol (PEG) 400 were purchased from Wako Pure Chemical Industries (Osaka, Japan). carboxyvinyl polymer (CP) (Hivis Wako105) was a gift from Wako. Films used in the adhesion test were composed of a single layer of various concentrations of CP (0％, 0.1 ％, 0.2％, or 0.3％ in the in vitro adhesion test and 0 ％, 0.1％, or 0.2％ in the in vivo adhesion test) as an adhesive adhering to an HPC base. Theˆlm used in the clinical evaluation had two layers (bicast), thê rst of which wasˆlm evaluated in the adhesion test (mucous membrane layer). Theˆrst layer adhering to the mucous membrane is composed of HPC, IM (0.5 ％ or 1％) as an analgesic, and CP (0.2％). IM (0.0015 g or 0.003 g) wasˆrst completely dissolved in ethanol, HPC was added, and then ethanol was added to make aˆnal volume of 30 ml for 0.9 g of HPC.
Ten milliliters of the mixed solution was cast in a ‰at
Te‰on dish 75 mm in diameter using a graduated pipette at a ‰ow rate of 10 ml/4 min, followed by drying overnight on a clean bench. For the second layer, 0.006 g of PEG as a softening agent 4) and HPC dissolved in ethanol were cast in a Te‰on dish, as described above. No precipitation of IM was detected.
Each application was assumed to use 1 cm 2 ofˆlm with 0.5％ or 1.0％ IM (IM content: 0.03 mg/cm 2 or 0.06 mg/cm 2 , respectively), 0.1％, 0.2％, or 0.3％ CP (CP content: 0.012 mg/cm 2 , 0.024 mg/cm 2 , or 0.036 mg/cm 2 , respectively), or 2％ PEG (PEG content: 0.24 mg/cm 2 ). Concentrations of IM or additives were calculated based on the amount of IM solution 5) or local anesthetic artiˆcial dentifrice (AD) lm 6) reported previously.
In Vitro Adhesion Test
One layer of experimentalˆlm consisted of four concentrations (0％, 0.1 ％, 0.2％, and 0.3％) of CP as an adhesion agent and HPC as a base component and was cut into 2-cm squares. After the experimentalˆlm was placed in the center of a nonwoven cloth (4C cloth, FK900 0138 EVA80, Kuraray Kura‰ex, Tokyo, Japan) that was cut into 3-cm×10-cm sections, the cloth was wetted with 39.6 ml of phosphate-buŠered saline (PBS) and folded in half, and 500 g of ‰at weight was placed on the cloth for 5 s and then removed. Five minutes after the experimentalˆlm was placed in the center of the cloth, one end of half of the cloth was pulled at a speed of 300 mm/min. The maximum force [kilogram-force (kgf)] of peeling was measured with a digital force gauge (ZP-50N, Imada, Aichi, Japan) at an angle of 90°by adjusting the slide system. The volume of PBS applied to the wet nonwoven cloth was calculated from the volume of saliva secreted in a Saxon test in aˆxed time so that it would adequately permeate the entire experimentalˆlm. 7) The experimental results were compared using ScheŠe's multiple-comparison test.
In Vivo Adhesion Test Thirteen healthy adult individuals gave informed consent to evaluate the adhesion of theˆlm. Before the adhesion test, they gargled with water to cleanse the entire mouth, and the designated site was dried by lightly wiping with gauze. The CP-containing adhesive side of theˆlm was then placed on the buccal mucosa. Three types ofˆlm (CP concentration 0％, 0.1％, or 0.2％) cut into 1-cm squares were placed in the center of the buccal mucosa, and the adhesion of theˆlm was checked with a mirror after 5, 10, and 15 min and then every 15 min for a total of 120 min. Eating, drinking, conversing, and exercising strenuously during the adhesion test were prohibited, and the mouth was kept closed as much as possible. Three percent gentian violet (1 mg/ cm 2 ) was added to theˆlm to permit visual assessment.
In Vitro Release of IM Four types ofˆlm (0.5 ％ IM, 0.5％ IM＋0.2％ CP, 1.0％ IM, 1.0％ IM＋ 0.2％ CP) were prepared and cut into circles with a diameter of 21 mm containing IM 30 mg (0.5％) and IM 60 mg (1.0％). A piece ofˆlm was placed in the center of a membraneˆlter (type HA, pore size 0.45 mm, Millipore, Billerica, MA, USA) in a verticaldiŠusion cell system (Hanson Research, Chatsworth, CA, USA), which wasˆlled with 15 ml of PBS 0.1 M and kept at 37°C. The units used in this study had an eŠective diŠusion area of 21 mm in diameter and a receptor compartment volume of 15 ml. The solvent was maintained at 37°C and continuously stirred using a magnetic stir bar. DiŠusion sample aliquots were removed through the sampling port using a syringe and replaced with an equivalent volume of fresh solvent. Released sample aliquots of IM were collected at 5, 10, 15, 30, 60, 120, and 360 min. The amount of IM that diŠused into the collected sample was measured using an HPLC system. The HPLC system was composed of two LC-10AD VP pumps, an SPD-10A VP ultraviolet detector, and an SIL-10AD VP autosampler from Shimadzu (Kyoto, Japan). The analysis was performed as previously described 8) on an octadecylsilica (ODS) column (150 mm×4.6 mm i.d.) with 5-mm particle size (Wakopak, Wakosil-II 5C18, Wako Pure Chemical Industries). The mobile phase of the assay consisted of sodium monophosphate buŠer 0.1 M and sodium acetate buŠer 0.2 M (8：2 v/v) at a ‰ow rate of 1.0 ml/min. Standard solution was prepared for each assay set at 0.25, 0.5, 2, 20, and 40 mg/ml.
Stability Test
Two groups of sampleˆlm (0.5 ％ IM＋0.2％ CP, 1％ IM＋0.2％ CP) selected for clinical evaluation were cut into 1×1-cm 2 sections and preserved under three diŠerent conditions, all in the shade: 37°C, room temperature, and 4°C for 0, 7, or 28 days. The amount of IM in theˆlm sections was measured after dissolving in 5 ml of phosphoric acid buŠer solution 0.1 M (pH 7.0), using the HPLC system described above.
Clinical Evaluation
Sixty-ˆve patients who had oral pain and visited the Maxillo-facial Surgery Department of Teikyo University Hospital gave written informed consent to participate in this evaluation. They were randomly allocated to four groups (0％ IM, 0.5％ IM, 0.5％ IM with PEG, 1.0％ IM). There were 21 cases of oral stomatitis, 14 cases of pain after surgery that included tooth extraction, 12 cases of ulcers (7 decubitus ulcers and 5 ulcers inside and on the edge of the tongue), 12 cases of wide painful areas of mucous membrane (2 lichen planus, 4 glossitis, 6 periodontal disease), and 6 other conditions.
The analgesic e‹cacy of theˆlm was evaluated 1, 3, and 5 min after application using the Visual Analogue Scale (VAS), with a horizontal line, 100 mm in length. The patients marked the line at the point they felt represented their perception of their current state compared with the pain before applying theˆlm, which was taken as 100％ (100 mm). The VAS score is determined by measuring in millimeters (％) from the left end of the line to the point marked by the patient. Exclusion criteria were used when the applied lm was removed. Fifty percent or greater pain relief was judged as eŠective. In addition, patients evaluated whether the texture of theˆlm would induce discomfort at the localized site of application. Any adverse eŠects of theˆlm were monitored for 1 week, which was the maximum period of clinical evaluation. This evaluation protocol was approved by the Committee for Medicinal Products of Teikyo University Hospital.
RESULTS AND DISCUSSION
Optimization of Mucoadhesive Film Preparation
When casting frequency was examined to produce a uniformly thickˆlm, two or three castings were found to provide adequate thickness (data not shown). The best method for producing theˆlm required two castings, which makes two-layeredˆlm. Films composed of two layers had a thickness of 79.6±8.9 mm.
E‹cacy of CP in the Adhesion Test
Based on the results of the in vitro adhesion test, theˆlm containing 0.1％ CP showed greater adhesion compared with controlˆlms (0.1 ％ CP vs. 0％ CP, p＜0.05). The addition of 0.2％ or more CP resulted in greater adhesion, but the adhesion was approximately the same between 0.2％ CP and 0.3％ CP (0.2％ CP, 0.3 ％ CP vs. 0％ CP, p＜0.01) (Fig. 1(a) ). More individuals with 0.2％ CPˆlm maintained theˆlm in place during the entire test period compared with 0.1 ％ CPˆlm or controlˆlm in the in vivo adhesion test (Fig. 1(b) ).
Based on the results of the in vitro and in vivo adhesion tests, the addition of 0.2％ CP increased the adhesion and the amount of CP for each use was 12 mg, which was well within safety limits compared with the maximum dose of 40 mg for dental or oral use and 150 mg for oral use. 9) E‹cacy of IM Release IM was released within 5 min from the 0.5％ or 1.0％ IMˆlm (6.7 mg 8.0 mg), and a 2-fold greater amount of IM was released from the 1.0％ˆlm compared with the 0.5％ˆlm. The addition of CP did not signiˆcantly change the amount of IM released (Fig. 2) . The amount of IM released from 0.5％ and 1.0％ IMˆlms was constant for 60 min, and 80％ of the IM was released within 120 min from all samples. The addition of CP did not aŠect IM release. Drug-release tests showed that IM was released from theˆlm within 5 min ofˆlm wetting. If theˆlm swelled or dissolved in saliva in the oral cavity, a rapid-onset analgesic eŠect would be expected. Eighty percent of IM was released within 120 min, indicating that disintegration of theˆlm was su‹ciently slow to allow drug release. Therefore thisˆlm formulation is expected to provide an adequate analgesic eŠect. Moreover, the results suggested that the addition of 0.2％ CP delays dissolution of theˆlm, thus providing a protective eŠect at a localized site.
Optimization of Storage Conditions and Expiration Period
Stability tests showed no change in the content of IM in all samples for 4 weeks after preparation ( Table 1) . However, at 28 days, the 0.5 ％ IMˆlm showed a reduction in the IM content to 98 ％. The expiration period for clinical use was therefore set at 4 weeks, and storage conditions were set at room temperature or cool conditions in the dark.
Clinical Evaluation All patients evaluated the taste and texture of theˆlm, and 50 patients evaluated pain relief withˆlm use at speciˆed times. Thirtyseven of 50 patients reported an analgesic eŠect after application of the IMˆlm. Furthermore, in the non-IM control samples, 7 patients still experienced oral pain despite the use of theˆlm. The mean maximum pain relief ratio in eŠective cases within 5 min was 84.4％±16.9％, 82.2％±10.3％, and 86.1％±16.1 ％, and the mean time until analgesic relief occurred was 2.0±1.6 min, 1.7±0.9 min, and 1.3±1.0 min in the 0.5％ IM, 0.5％ IM with PEG, and 1.0％ IM groups, respectively ( Table 2 ). An analgesic eŠect was achieved within 1 min after applying theˆlm in 13 cases (61.9％) with 0.5％ IM and in 15 cases (93.7 ％) with 1.0％ IM. Maximum pain relief rates for 0.5 ％ IM and 1.0％ IM were signiˆcantly greater than the controls ( p＜0.01) (Fig. 3) . In addition, when classiˆed by disease, the average maximum pain relief rate was 93％ of stomatitis, 88％ of ulcer (decubitus ulcer and tongue ulcer), and 80％ of pain after surgery and wide mucous membrane lesion patients (data not shown). The number of individuals complaining of discomfort at the localized site where thê lm was applied was 3 of 17 (17.6％) in theˆlm with Table 3 ). The safety ofˆlm application was also monitored in this period among the individuals who received either of thoseˆlm preparations. Two of 65 individuals reported numbness at theˆlm site 1 4 min after application. Exfoliation of theˆlm or gargling was recommended in those cases, the symptoms were relieved, and there was no eŠect on treatment or patient condition afterˆlm application. There were no other complaints regardingˆlm application. In terms of clinical e‹cacy, 6 of 16 individuals in the high-dose IMˆlm group reported 100％ pain relief within 1 min, and all (100％) showed greater than 50％ pain relief using the VAS method (eŠec-tive). Rapid, eŠective analgesia was therefore obtained with theˆlm formulation containing 1％ IM compared with the lower dose. In individual cases, marked analgesic eŠects were seen, especially when pain was localized and the trigger point of pain was clear, in cases with spontaneous pain, or in cases with severe, intolerable pain. However, the duration of the analgesic eŠect withˆlm application could not be deˆnitively determined in this study, although a maximum sustained analgesic eŠect of 7 h was observed in 6 patients in whom investigation was possible. The persistence of the analgesic action of theˆlm in this study was almost equal to that of dibucaineˆlm prepared using conventional methods and used in other medicalˆelds, which maintains its analgesic eŠects for less than 5.5 h. 6) In addition, the IM content of theˆlm for one application was approximately 1/400 or 1/800 that of the standard oral dose. Therefore this formulation is expected to be useful in patients in whom normal doses cannot be used due to adverse side eŠects.
